Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.
(EN) Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by formula (I) and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.(FR) La présente invention décrit de nouveaux inhibiteurs de 3-hydroxy-3-méthylglutaryl-coenzyme A réductase utiles comme agents antihypercholestérolémiques et représentés par la formule (I), ainsi que les acides hydroxy à anneaux ouverts obtenus à partir de ces composés et des sels pharmaceutiquement acceptables de ces composés. Des préparations pharmaceutiques contenant ces composés et un procédé permettant d'inhiber la biosynthèse de choléstérol avec eux sont également décrits.